We evaluated our 1- and 2-year patency rates as well as the clinically driven reintervention rates in our patients with diffuse de novo and instent restenotic FP atherosclerotic lesions greater than 20 cm who received the Zilver PTX DES.
Dr. Walker comments on Poli and colleagues’ article on the implantation of the ACURATE neo transcatheter aortic valve to treat a patient with severe aortic stenosis via a subclavian artery that was surgically exposed.
Superficial femoral artery (SFA) is an area of intense research interest and multiple options for treatment. In this Q&A, Gary Ansel, MD, FACC, explains the takeaways from recently released data on various devices and therapies.
Craig Walker, MD, Clinical Editor
Cardiovascular Institute of the South
Tulane Medical School
Lauren LeBano, Managing Editor, Vascular Disease Management
104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520